Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Meredith Regan.
Connection Strength

0.125
  1. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol. 2003; 14 Suppl 1:i21-7.
    View in: PubMed
    Score: 0.066
  2. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur J Haematol Suppl. 2001 Jul; 64:56-62.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.